The University of Southampton
University of Southampton Institutional Repository
Warning ePrints Soton is experiencing an issue with some file downloads not being available. We are working hard to fix this. Please bear with us.

A cost-effectiveness analysis of multigene testing for all patients with breast cancer

A cost-effectiveness analysis of multigene testing for all patients with breast cancer
A cost-effectiveness analysis of multigene testing for all patients with breast cancer
Importance Moving to multigene testing for all women with breast cancer (BC) could identify many more mutation carriers who can benefit from precision prevention. However, the cost-effectiveness of this approach remains unaddressed.

Objective To estimate incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with BC compared with the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria.

Design, Setting, and Participants This cost-effectiveness microsimulation modeling study compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical criteria (strategy B) in United Kingdom (UK) and US populations. Data were obtained from 11 836 patients in population-based BC cohorts (regardless of FH) recruited to 4 large research studies. Data were collected and analyzed from January 1, 2018, through June 8, 2019. The time horizon is lifetime. Payer and societal perspectives are presented. Probabilistic and 1-way sensitivity analyses evaluate model uncertainty.

Interventions In strategy A, all women with BC underwent BRCA1/BRCA2/PALB2 testing. In strategy B, only women with BC fulfilling FH or clinical criteria underwent BRCA testing. Affected BRCA/PALB2 carriers could undertake contralateral preventive mastectomy; BRCA carriers could choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation carriers underwent cascade testing. Unaffected relative carriers could undergo magnetic resonance imaging or mammography screening, chemoprevention, or risk-reducing mastectomy for BC risk and RRSO for ovarian cancer (OC) risk.

Main Outcomes and Measures Incremental cost-effectiveness ratio (ICER) was calculated as incremental cost per quality-adjusted life-year (QALY) gained and compared with standard £30 000/QALY and $100 000/QALY UK and US thresholds, respectively. Incidence of OC, BC, excess deaths due to heart disease, and the overall population effects were estimated.

Results BRCA1/BRCA2/PALB2 multigene testing for all patients detected with BC annually would cost £10 464/QALY (payer perspective) or £7216/QALY (societal perspective) in the United Kingdom or $65 661/QALY (payer perspective) or $61 618/QALY (societal perspective) in the United States compared with current BRCA testing based on clinical criteria or FH. This is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis, unselected multigene testing remained cost-effective for 98% to 99% of UK and 64% to 68% of US health system simulations. One year’s unselected multigene testing could prevent 2101 cases of BC and OC and 633 deaths in the United Kingdom and 9733 cases of BC and OC and 2406 deaths in the United States. Correspondingly, 8 excess deaths due to heart disease occurred in the United Kingdom and 35 in the United States annually.

Conclusions and Relevance This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.
2374-2437
Sun, Li
582976f8-f598-45ec-922c-df89ef1003ef
Brentnall, Adam
c45c5b0c-298d-4ed8-921e-8fe7ece94aaf
Patel, Shreeya
7284371f-c300-4043-ae7a-6a99a3c80e1f
Buist, Diana S. M.
e3726749-0888-4698-b4dc-43071dff34bd
Bowles, Erin J. A.
633fba8b-5f6a-4be8-9da6-f90f3119b56d
Evans, D. Gareth R.
879bb945-4b7f-4cd6-b62c-f6b75f45f02c
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Hopper, John
29eb4dae-cc6e-446e-8432-92f14a7f3c76
Li, Shuai
24ddf1da-2775-40dd-96c9-759e716072c0
Southey, Melissa
d947202d-9257-4d1c-bf1d-677af3580635
Duffy, Stephen
5b52362d-cad8-47a7-8549-5adcd7359a0e
Cuzick, Jack
c25cf66b-64c3-43b4-a4a5-84092fb1080c
Dos Santos Silva, Isabel
f8366712-2545-4c3d-921d-ae7dc202bb29
Miners, Alec
00f4a0ec-6a07-44c7-b1a4-f44c5b3fb400
Sadique, Zia
cd77e961-1c90-47b9-af27-e99ce83ea236
Yang, Li
e83b05d2-023a-4a02-b90f-e9b4ee879055
Legood, Rosa
2fe4cdd0-cde3-4fa3-ba20-7d0f050b6e3b
Manchanda, Ranjit
fcf99156-4522-406c-a935-f9885efb224c
Sun, Li
582976f8-f598-45ec-922c-df89ef1003ef
Brentnall, Adam
c45c5b0c-298d-4ed8-921e-8fe7ece94aaf
Patel, Shreeya
7284371f-c300-4043-ae7a-6a99a3c80e1f
Buist, Diana S. M.
e3726749-0888-4698-b4dc-43071dff34bd
Bowles, Erin J. A.
633fba8b-5f6a-4be8-9da6-f90f3119b56d
Evans, D. Gareth R.
879bb945-4b7f-4cd6-b62c-f6b75f45f02c
Eccles, Diana
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Hopper, John
29eb4dae-cc6e-446e-8432-92f14a7f3c76
Li, Shuai
24ddf1da-2775-40dd-96c9-759e716072c0
Southey, Melissa
d947202d-9257-4d1c-bf1d-677af3580635
Duffy, Stephen
5b52362d-cad8-47a7-8549-5adcd7359a0e
Cuzick, Jack
c25cf66b-64c3-43b4-a4a5-84092fb1080c
Dos Santos Silva, Isabel
f8366712-2545-4c3d-921d-ae7dc202bb29
Miners, Alec
00f4a0ec-6a07-44c7-b1a4-f44c5b3fb400
Sadique, Zia
cd77e961-1c90-47b9-af27-e99ce83ea236
Yang, Li
e83b05d2-023a-4a02-b90f-e9b4ee879055
Legood, Rosa
2fe4cdd0-cde3-4fa3-ba20-7d0f050b6e3b
Manchanda, Ranjit
fcf99156-4522-406c-a935-f9885efb224c

Sun, Li, Brentnall, Adam, Patel, Shreeya, Buist, Diana S. M., Bowles, Erin J. A., Evans, D. Gareth R., Eccles, Diana, Hopper, John, Li, Shuai, Southey, Melissa, Duffy, Stephen, Cuzick, Jack, Dos Santos Silva, Isabel, Miners, Alec, Sadique, Zia, Yang, Li, Legood, Rosa and Manchanda, Ranjit (2019) A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncology. (doi:10.1001/jamaoncol.2019.3323).

Record type: Article

Abstract

Importance Moving to multigene testing for all women with breast cancer (BC) could identify many more mutation carriers who can benefit from precision prevention. However, the cost-effectiveness of this approach remains unaddressed.

Objective To estimate incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with BC compared with the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria.

Design, Setting, and Participants This cost-effectiveness microsimulation modeling study compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical criteria (strategy B) in United Kingdom (UK) and US populations. Data were obtained from 11 836 patients in population-based BC cohorts (regardless of FH) recruited to 4 large research studies. Data were collected and analyzed from January 1, 2018, through June 8, 2019. The time horizon is lifetime. Payer and societal perspectives are presented. Probabilistic and 1-way sensitivity analyses evaluate model uncertainty.

Interventions In strategy A, all women with BC underwent BRCA1/BRCA2/PALB2 testing. In strategy B, only women with BC fulfilling FH or clinical criteria underwent BRCA testing. Affected BRCA/PALB2 carriers could undertake contralateral preventive mastectomy; BRCA carriers could choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation carriers underwent cascade testing. Unaffected relative carriers could undergo magnetic resonance imaging or mammography screening, chemoprevention, or risk-reducing mastectomy for BC risk and RRSO for ovarian cancer (OC) risk.

Main Outcomes and Measures Incremental cost-effectiveness ratio (ICER) was calculated as incremental cost per quality-adjusted life-year (QALY) gained and compared with standard £30 000/QALY and $100 000/QALY UK and US thresholds, respectively. Incidence of OC, BC, excess deaths due to heart disease, and the overall population effects were estimated.

Results BRCA1/BRCA2/PALB2 multigene testing for all patients detected with BC annually would cost £10 464/QALY (payer perspective) or £7216/QALY (societal perspective) in the United Kingdom or $65 661/QALY (payer perspective) or $61 618/QALY (societal perspective) in the United States compared with current BRCA testing based on clinical criteria or FH. This is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis, unselected multigene testing remained cost-effective for 98% to 99% of UK and 64% to 68% of US health system simulations. One year’s unselected multigene testing could prevent 2101 cases of BC and OC and 633 deaths in the United Kingdom and 9733 cases of BC and OC and 2406 deaths in the United States. Correspondingly, 8 excess deaths due to heart disease occurred in the United Kingdom and 35 in the United States annually.

Conclusions and Relevance This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.

Text
jamaoncology_sun_2019_oi_190067 - Version of Record
Available under License Creative Commons Attribution.
Download (498kB)

More information

Accepted/In Press date: 19 June 2019
e-pub ahead of print date: 3 October 2019

Identifiers

Local EPrints ID: 434948
URI: http://eprints.soton.ac.uk/id/eprint/434948
ISSN: 2374-2437
PURE UUID: 52dae486-bbfe-481b-8a47-38e394cb62df
ORCID for Diana Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 17 Oct 2019 16:30
Last modified: 10 Jan 2022 02:34

Export record

Altmetrics

Contributors

Author: Li Sun
Author: Adam Brentnall
Author: Shreeya Patel
Author: Diana S. M. Buist
Author: Erin J. A. Bowles
Author: D. Gareth R. Evans
Author: Diana Eccles ORCID iD
Author: John Hopper
Author: Shuai Li
Author: Melissa Southey
Author: Stephen Duffy
Author: Jack Cuzick
Author: Isabel Dos Santos Silva
Author: Alec Miners
Author: Zia Sadique
Author: Li Yang
Author: Rosa Legood
Author: Ranjit Manchanda

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×